: Chemotherapy is not a traditional mainstay of upfront treatment for low-grade gliomas. Some data support temozolomide as adjuvant therapy, and it is included as a category 2B recommendation based on nonuniform panel consensus. A phase II trial of temozolomide
Search Results
Louis Burt Nabors, Mario Ammirati, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Moshe H. Maor, Paul L. Moots, Tara Morrison, Maciej M. Mrugala, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, David Tran, Nam Tran, Frank D. Vrionis, Patrick Y. Wen, Nicole McMillian, and Maria Ho
Vivek Verma, Swati M. Surkar, Eric D. Brooks, Charles B. Simone II, and Chi Lin
guidelines, visit NCCN.org . 2. Macdonald OK Crane CH . Palliative and postoperative radiotherapy in biliary tract cancer . Surg Oncol Clin N Am 2002 ; 11 : 941 – 954 . 3. Hoehn RS Wima K Ertel AE . Adjuvant therapy for
Deirdre R. Pachman, Kathryn Ruddy, Lindsey R. Sangaralingham, Axel Grothey, Nilay D. Shah, Andreas S. Beutler, Joleen M. Hubbard, and Charles L. Loprinzi
across the world, including an adjuvant therapy trial (N04C7) that had accrued approximately 100 patients. However, a subsequent review of the data monitoring committee report showed that it was aberrant, and a subsequent Letter to the Editor in JCO
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar
these with patients and families and pick the best approach on a case-by-case basis. Adjuvant Therapy: Oliver et al 35 reported on the results of a trial that randomized 1477 patients with stage 1 testicular cancer to undergo either radiotherapy or
Aaron M. Cheng and Douglas E. Wood
understaged may not receive the appropriate adjuvant therapy, and this is likely to result in survival differences now that adjuvant therapy has become standard of care for resected stage II or greater lung cancer. The NCCN Guidelines for Non–Small Cell Lung
Presenters: Crystal S. Denlinger, Kristina A. Matkowskyj, and Mary F. Mulcahy
-free survival, there was clear benefit for nivolumab as adjuvant therapy (22.4 vs 11.0 months; HR, 0.69; P =.0003), with the benefit sustained over time. Nivolumab was favored in all subgroups. “This is the most robust data we have seen showing any benefit
Julia T. van Groningen, Pieter van Hagen, Rob A.E.M. Tollenaar, Jurriaan B. Tuynman, Perla J. Marang-van de Mheen, Pascal G. Doornebosch, Pieter J. Tanis, Eelco J.R. de Graaf, and on behalf of the Dutch Colorectal Audit
evidence. 16 Long-term outcomes of both neoadjuvant and adjuvant therapy and local excision need to be confirmed by large prospective randomized trials. Currently, the Dutch national guidelines consider these treatments experimental and state that these
Presenters: Dara L. Aisner and Gregory J. Riely
NCCN Guidelines now list osimertinib as an option for adjuvant therapy in patients with resectable stage IIB–IIIA or high-risk stage IB–IIA NSCLC harboring EGFR mutations who received previous adjuvant chemotherapy or are ineligible to receive
Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy, and Aditya Bardia
counterparts, which might be due to aggressive tumor biology and lower efficacy of adjuvant therapy, including endocrine therapy for HR-positive breast cancer in young women. For example, among patients with HR-positive disease, there are data in a Korean
Robin K. Kelley, Stephanie L. Van Bebber, Kathryn A. Phillips, and Alan P. Venook
tumor specimens of patients enrolled in randomized studies of adjuvant 5-fluorouracil with levamisole or leucovorin compared with no adjuvant therapy. 98 This study showed no improvement in overall survival in patients with stage II and III colon cancer
